Comparative efficacy and safety of adalimumab biosimilars and adalimumab in patients with rheumatoid arthritis presenting an insufficient response to methotrexate: a network meta-analysis.

Published in: Zeitschrift fur Rheumatologie (2021)

No significant difference was detected between adalimumab biosimilars and the originator in terms of ACR20 response rates and SAEs in the studied patients.

Keyphrases

rheumatoid arthritis
juvenile idiopathic arthritis
end stage renal disease
ejection fraction
hidradenitis suppurativa
ulcerative colitis
peritoneal dialysis
high dose
case report
low dose
patient reported outcomes